EYPT logo

EYEPOINT INC

EYPTNASDAQ
πŸ† #4448 by market capEarnings Mar 2 Β· PostUS Equity
$0.23β–Ό $0.03 (βˆ’11.69%)
Market closed Β· at close
πŸ””
Track EYPT
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 11.7%
7dβ–Ό 24.4%
14dβ–Ό 34.9%
30dβ–Ό 42.2%
ytdβ–Ό 98.7%
1yβ–Ό 98.3%
🏦Market Cap
$20M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-94.6%
Declining
πŸ“ŠGross Margin
41.8%
Healthy
πŸ’΅FCF Margin
2030.3%
Strong
βš–οΈP/S Ratio
9.6x
Elevated
Otter Score
40
Weak

Trading Snapshot

Day Range
$0.23 – $0.26
52-Week Range
$0.23 – $19.11
Volume (shares)
168,943
Avg Volume (shares)
β€”
Shares Outstanding
86.2M
Next Earnings
2027-03-02

Fundamentals Snapshot

Annual Revenue
$31M
Last Q Revenue
$756,000
P/E Ratio
β€”
P/S Ratio
9.6x
EPS (TTM)
$-3.74
Dividend Yield
β€”
Dilution (1yr)
+28.6%
EYPT logo

EYEPOINT INC

EYPT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$31Mβ–Ό βˆ’27.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
93.4%β–² +2.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$243Mβ–² +66.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$243Mβ–² +86.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
83.0Mβ–² +28.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$79Mβ–² +$1M YoY
StockOtter Β· stockotter.space

About EYEPOINT INC

EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone acetonide, which targets chronic non-infectious uveitis impacting the posterior segment of the eye. The company also offers DEXYCU, a dexamethasone intraocular suspension, utilized to manage post-operative ocular inflammation, such as that occurring after cataract surgery. Looking ahead, EyePoint is actively developing several pipeline therapies. This includes EYP-1901, a novel, bioerodible tyrosine kinase inhibitor currently formulated for twice-yearly administration, which is under development for conditions like wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Additionally, YUTIQ50 is being advanced as a treatment for chronic non-infectious uveitis affecting the posterior region of the eye. To bolster its market reach and development efforts, the company maintains strategic alliances with entities such as Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. Furthermore, a commercial collaboration with ImprimisRx PA, Inc. specifically focuses on the joint promotion of DEXYCU for inflammation following ocular surgery. Incorporated in 1987, the organization was previously known as pSivida Corp. before officially rebranding as EyePoint Pharmaceuticals, Inc. in March 2018. Its corporate headquarters are situated in Watertown, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
40/100
Analyst data unavailable.

Latest News & Updates

News unavailable.